Department of Anesthesiology, Linyi Cancer Hospital, Linyi City, China.
J Clin Pharm Ther. 2020 Oct;45(5):1039-1049. doi: 10.1111/jcpt.13133. Epub 2020 Apr 7.
The comparative efficacy of ancillary drugs on sevoflurane-related emergence agitation (EA) in paediatric anaesthesia for adenotonsillectomy remains unclear. The purpose of this Bayesian network meta-analysis was to investigate the efficacy of ancillary drugs on sevoflurane-related EA in paediatric anaesthesia for adenotonsillectomy.
MEDLINE, Embase, the Cochrane Library and Web of Science databases were electronically searched to identify randomized controlled trials (RCTs) of different ancillary drugs used in adenotonsillectomy from inception to April 2019. Two reviewers independently screened the literature, extracted data and assessed the risk of bias in included studies. Subsequently, a network meta-analysis was performed using the R software and RevMan 5.3 software.
We included 25 RCTs, involving 2151 participants. The proportion of patients with sevoflurane-related EA was significantly lower in the dexmedetomidine, ketamine, propofol, fentanyl, midazolam, sufentanil, remifentanil and clonidine groups than in the placebo group (P < .05). Fentanyl was superior to sufentanil (P < .05), whereas dexmedetomidine was superior to fentanyl (P < .05). Among ancillary drugs, dexmedetomidine (90.04%) showed the highest possibility of reducing the risk of EA, followed by fentanyl (87.45%), remifentanil (63.85%), ketamine (52.07%), midazolam (51.27%), clonidine (49.94%), propofol (29.89%), sufentanil (21.38%) and placebo (4.09%).
Evidence suggests that the effects of dexmedetomidine in reducing the risk of sevoflurane-related EA in paediatric anaesthesia for adenotonsillectomy were better than the effects of other drugs. However, large, high-quality RCTs are required to further confirm this.
在小儿扁桃体腺样体切除术的全身麻醉中,辅助药物对七氟醚相关苏醒期躁动(EA)的比较疗效尚不清楚。本贝叶斯网状荟萃分析的目的是研究辅助药物对小儿扁桃体腺样体切除术全身麻醉中七氟醚相关 EA 的疗效。
通过电子检索 MEDLINE、Embase、Cochrane 图书馆和 Web of Science 数据库,从建库至 2019 年 4 月,检索了不同辅助药物用于扁桃体腺样体切除术的随机对照试验(RCT)。两名审查员独立筛选文献、提取数据并评估纳入研究的偏倚风险。随后,使用 R 软件和 RevMan 5.3 软件进行网络荟萃分析。
我们纳入了 25 项 RCT,涉及 2151 名参与者。与安慰剂组相比,右美托咪定、氯胺酮、异丙酚、芬太尼、咪达唑仑、舒芬太尼、瑞芬太尼和可乐定组的七氟醚相关 EA 患者比例明显降低(P<0.05)。芬太尼优于舒芬太尼(P<0.05),而右美托咪定优于芬太尼(P<0.05)。在辅助药物中,右美托咪定(90.04%)降低 EA 风险的可能性最高,其次是芬太尼(87.45%)、瑞芬太尼(63.85%)、氯胺酮(52.07%)、咪达唑仑(51.27%)、可乐定(49.94%)、异丙酚(29.89%)、舒芬太尼(21.38%)和安慰剂(4.09%)。
有证据表明,右美托咪定在降低小儿扁桃体腺样体切除术全身麻醉中七氟醚相关 EA 风险方面的效果优于其他药物。然而,需要更大规模、高质量的 RCT 进一步证实这一点。